Cluster Analysis Using Anti-Aminoacyl-tRNA Synthetases and SS-A/Ro52 antibodies in Patients with Polymyositis/Dermatomyositis

Keiji Ohashi, Kenei Sada, Yu Nakai, Shun Matsushima, Yosuke Asano, Keigo Hayashi, Yuriko Yamamura, Sumie Hiramatsu, Yoshia Miyawaki, Michiko Morishita, Takayuki Katsuyama, Eri Katsuyama, Haruki Watanabe, Noriko Tatebe, Mariko Narazaki, Yoshinori Matsumoto, Katsue Sunahori Watanabe, Tomoko Kawabata, Jun Wada

Research output: Contribution to journalArticle

Abstract

Objective Although several autoantibodies have been identified for polymyositis/dermatomyositis (PM/DM) diagnosis, the clinical impact of these antibodies is yet to be elucidated. Methods Patients with PM/DM at Okayama University Hospital from 2012 to 2016 were historically enrolled, and antibody profiles were analyzed using line immunoassay. Hierarchical cluster analysis was performed based on serological analysis of anti-aminoacyl-tRNA synthetase (ARS) antibodies, including anti-Jo-1, PL-7, PL-12, EJ, OJ, and SS-A/Ro-52 antibodies. Clinical symptoms and relapse proportions were compared among these clusters. Results Sixty-one patients were enrolled in this study: 28 were diagnosed with PM, and 33 were diagnosed with DM. The following 3 clusters were determined: 1 (n = 10), anti-Jo-1 and anti-SS-A/Ro-52 antibodies double positive (10/10, 100%); 2 (n = 24), anti-SS-A/Ro-52 antibody positive (20/24, 83%), anti-Jo-1 antibody negative (24/24, 100%), and anti-ARS antibodies (excluding anti-Jo-1 antibody) positive (15/24, 63%); and 3 (n = 27), anti-Jo-1 and anti-SS-A/Ro52 antibodies double negative (26/27, 96%). The proportion of patients who relapsed was significantly lower in cluster 3 than it was in clusters 1 and 2 (risk ratio, 0.37; 95% confidence interval, 0.17-0.83; p = 0.026 and risk ratio, 0.42; 95% confidence interval, 0.20-0.89; P = 0.019, respectively). There was no difference in the proportion of relapsed patients between clusters 1 and 2. Conclusions Our cluster analysis shows that anti-SS-A/Ro52 or any anti-ARS antibodies or both might be relevant to clinical outcomes.

Original languageEnglish
Pages (from-to)246-251
Number of pages6
JournalJournal of Clinical Rheumatology
Volume25
Issue number6
DOIs
Publication statusPublished - Sep 1 2019

Fingerprint

Amino Acyl-tRNA Synthetases
Dermatomyositis
Cluster Analysis
Antibodies
Anti-Idiotypic Antibodies
Odds Ratio
Confidence Intervals
Immunoassay
Autoantibodies
Recurrence
SS-A antibodies
Jo-1 antibody

Keywords

  • cluster analysis
  • dermatomyositis
  • line immunoassay
  • polymyositis

ASJC Scopus subject areas

  • Rheumatology

Cite this

Cluster Analysis Using Anti-Aminoacyl-tRNA Synthetases and SS-A/Ro52 antibodies in Patients with Polymyositis/Dermatomyositis. / Ohashi, Keiji; Sada, Kenei; Nakai, Yu; Matsushima, Shun; Asano, Yosuke; Hayashi, Keigo; Yamamura, Yuriko; Hiramatsu, Sumie; Miyawaki, Yoshia; Morishita, Michiko; Katsuyama, Takayuki; Katsuyama, Eri; Watanabe, Haruki; Tatebe, Noriko; Narazaki, Mariko; Matsumoto, Yoshinori; Sunahori Watanabe, Katsue; Kawabata, Tomoko; Wada, Jun.

In: Journal of Clinical Rheumatology, Vol. 25, No. 6, 01.09.2019, p. 246-251.

Research output: Contribution to journalArticle

Ohashi, K, Sada, K, Nakai, Y, Matsushima, S, Asano, Y, Hayashi, K, Yamamura, Y, Hiramatsu, S, Miyawaki, Y, Morishita, M, Katsuyama, T, Katsuyama, E, Watanabe, H, Tatebe, N, Narazaki, M, Matsumoto, Y, Sunahori Watanabe, K, Kawabata, T & Wada, J 2019, 'Cluster Analysis Using Anti-Aminoacyl-tRNA Synthetases and SS-A/Ro52 antibodies in Patients with Polymyositis/Dermatomyositis', Journal of Clinical Rheumatology, vol. 25, no. 6, pp. 246-251. https://doi.org/10.1097/RHU.0000000000000836
Ohashi, Keiji ; Sada, Kenei ; Nakai, Yu ; Matsushima, Shun ; Asano, Yosuke ; Hayashi, Keigo ; Yamamura, Yuriko ; Hiramatsu, Sumie ; Miyawaki, Yoshia ; Morishita, Michiko ; Katsuyama, Takayuki ; Katsuyama, Eri ; Watanabe, Haruki ; Tatebe, Noriko ; Narazaki, Mariko ; Matsumoto, Yoshinori ; Sunahori Watanabe, Katsue ; Kawabata, Tomoko ; Wada, Jun. / Cluster Analysis Using Anti-Aminoacyl-tRNA Synthetases and SS-A/Ro52 antibodies in Patients with Polymyositis/Dermatomyositis. In: Journal of Clinical Rheumatology. 2019 ; Vol. 25, No. 6. pp. 246-251.
@article{d61a9e7fd7e54109bc24ca744aae02b4,
title = "Cluster Analysis Using Anti-Aminoacyl-tRNA Synthetases and SS-A/Ro52 antibodies in Patients with Polymyositis/Dermatomyositis",
abstract = "Objective Although several autoantibodies have been identified for polymyositis/dermatomyositis (PM/DM) diagnosis, the clinical impact of these antibodies is yet to be elucidated. Methods Patients with PM/DM at Okayama University Hospital from 2012 to 2016 were historically enrolled, and antibody profiles were analyzed using line immunoassay. Hierarchical cluster analysis was performed based on serological analysis of anti-aminoacyl-tRNA synthetase (ARS) antibodies, including anti-Jo-1, PL-7, PL-12, EJ, OJ, and SS-A/Ro-52 antibodies. Clinical symptoms and relapse proportions were compared among these clusters. Results Sixty-one patients were enrolled in this study: 28 were diagnosed with PM, and 33 were diagnosed with DM. The following 3 clusters were determined: 1 (n = 10), anti-Jo-1 and anti-SS-A/Ro-52 antibodies double positive (10/10, 100{\%}); 2 (n = 24), anti-SS-A/Ro-52 antibody positive (20/24, 83{\%}), anti-Jo-1 antibody negative (24/24, 100{\%}), and anti-ARS antibodies (excluding anti-Jo-1 antibody) positive (15/24, 63{\%}); and 3 (n = 27), anti-Jo-1 and anti-SS-A/Ro52 antibodies double negative (26/27, 96{\%}). The proportion of patients who relapsed was significantly lower in cluster 3 than it was in clusters 1 and 2 (risk ratio, 0.37; 95{\%} confidence interval, 0.17-0.83; p = 0.026 and risk ratio, 0.42; 95{\%} confidence interval, 0.20-0.89; P = 0.019, respectively). There was no difference in the proportion of relapsed patients between clusters 1 and 2. Conclusions Our cluster analysis shows that anti-SS-A/Ro52 or any anti-ARS antibodies or both might be relevant to clinical outcomes.",
keywords = "cluster analysis, dermatomyositis, line immunoassay, polymyositis",
author = "Keiji Ohashi and Kenei Sada and Yu Nakai and Shun Matsushima and Yosuke Asano and Keigo Hayashi and Yuriko Yamamura and Sumie Hiramatsu and Yoshia Miyawaki and Michiko Morishita and Takayuki Katsuyama and Eri Katsuyama and Haruki Watanabe and Noriko Tatebe and Mariko Narazaki and Yoshinori Matsumoto and {Sunahori Watanabe}, Katsue and Tomoko Kawabata and Jun Wada",
year = "2019",
month = "9",
day = "1",
doi = "10.1097/RHU.0000000000000836",
language = "English",
volume = "25",
pages = "246--251",
journal = "Journal of Clinical Rheumatology",
issn = "1076-1608",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Cluster Analysis Using Anti-Aminoacyl-tRNA Synthetases and SS-A/Ro52 antibodies in Patients with Polymyositis/Dermatomyositis

AU - Ohashi, Keiji

AU - Sada, Kenei

AU - Nakai, Yu

AU - Matsushima, Shun

AU - Asano, Yosuke

AU - Hayashi, Keigo

AU - Yamamura, Yuriko

AU - Hiramatsu, Sumie

AU - Miyawaki, Yoshia

AU - Morishita, Michiko

AU - Katsuyama, Takayuki

AU - Katsuyama, Eri

AU - Watanabe, Haruki

AU - Tatebe, Noriko

AU - Narazaki, Mariko

AU - Matsumoto, Yoshinori

AU - Sunahori Watanabe, Katsue

AU - Kawabata, Tomoko

AU - Wada, Jun

PY - 2019/9/1

Y1 - 2019/9/1

N2 - Objective Although several autoantibodies have been identified for polymyositis/dermatomyositis (PM/DM) diagnosis, the clinical impact of these antibodies is yet to be elucidated. Methods Patients with PM/DM at Okayama University Hospital from 2012 to 2016 were historically enrolled, and antibody profiles were analyzed using line immunoassay. Hierarchical cluster analysis was performed based on serological analysis of anti-aminoacyl-tRNA synthetase (ARS) antibodies, including anti-Jo-1, PL-7, PL-12, EJ, OJ, and SS-A/Ro-52 antibodies. Clinical symptoms and relapse proportions were compared among these clusters. Results Sixty-one patients were enrolled in this study: 28 were diagnosed with PM, and 33 were diagnosed with DM. The following 3 clusters were determined: 1 (n = 10), anti-Jo-1 and anti-SS-A/Ro-52 antibodies double positive (10/10, 100%); 2 (n = 24), anti-SS-A/Ro-52 antibody positive (20/24, 83%), anti-Jo-1 antibody negative (24/24, 100%), and anti-ARS antibodies (excluding anti-Jo-1 antibody) positive (15/24, 63%); and 3 (n = 27), anti-Jo-1 and anti-SS-A/Ro52 antibodies double negative (26/27, 96%). The proportion of patients who relapsed was significantly lower in cluster 3 than it was in clusters 1 and 2 (risk ratio, 0.37; 95% confidence interval, 0.17-0.83; p = 0.026 and risk ratio, 0.42; 95% confidence interval, 0.20-0.89; P = 0.019, respectively). There was no difference in the proportion of relapsed patients between clusters 1 and 2. Conclusions Our cluster analysis shows that anti-SS-A/Ro52 or any anti-ARS antibodies or both might be relevant to clinical outcomes.

AB - Objective Although several autoantibodies have been identified for polymyositis/dermatomyositis (PM/DM) diagnosis, the clinical impact of these antibodies is yet to be elucidated. Methods Patients with PM/DM at Okayama University Hospital from 2012 to 2016 were historically enrolled, and antibody profiles were analyzed using line immunoassay. Hierarchical cluster analysis was performed based on serological analysis of anti-aminoacyl-tRNA synthetase (ARS) antibodies, including anti-Jo-1, PL-7, PL-12, EJ, OJ, and SS-A/Ro-52 antibodies. Clinical symptoms and relapse proportions were compared among these clusters. Results Sixty-one patients were enrolled in this study: 28 were diagnosed with PM, and 33 were diagnosed with DM. The following 3 clusters were determined: 1 (n = 10), anti-Jo-1 and anti-SS-A/Ro-52 antibodies double positive (10/10, 100%); 2 (n = 24), anti-SS-A/Ro-52 antibody positive (20/24, 83%), anti-Jo-1 antibody negative (24/24, 100%), and anti-ARS antibodies (excluding anti-Jo-1 antibody) positive (15/24, 63%); and 3 (n = 27), anti-Jo-1 and anti-SS-A/Ro52 antibodies double negative (26/27, 96%). The proportion of patients who relapsed was significantly lower in cluster 3 than it was in clusters 1 and 2 (risk ratio, 0.37; 95% confidence interval, 0.17-0.83; p = 0.026 and risk ratio, 0.42; 95% confidence interval, 0.20-0.89; P = 0.019, respectively). There was no difference in the proportion of relapsed patients between clusters 1 and 2. Conclusions Our cluster analysis shows that anti-SS-A/Ro52 or any anti-ARS antibodies or both might be relevant to clinical outcomes.

KW - cluster analysis

KW - dermatomyositis

KW - line immunoassay

KW - polymyositis

UR - http://www.scopus.com/inward/record.url?scp=85071376210&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071376210&partnerID=8YFLogxK

U2 - 10.1097/RHU.0000000000000836

DO - 10.1097/RHU.0000000000000836

M3 - Article

C2 - 29933322

AN - SCOPUS:85071376210

VL - 25

SP - 246

EP - 251

JO - Journal of Clinical Rheumatology

JF - Journal of Clinical Rheumatology

SN - 1076-1608

IS - 6

ER -